As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

20 Dec 2024. An Open Letter to: Dennis J. Selkoe, M.D. The Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School. Co-Director, Center for Neurologic Diseases, Department ...

Kenneth Kosik University of California, Santa Barbara; Posted: 16 Sep 2024 Francisco Lopera: A Memory and a Tribute. Autumn already!–But why regret an eternal sun if we are embarked on the discovery ...

Martin Ingelsson University of Toronto ; Posted: 27 Jun 2024 This yet-to-be-peer-reviewed manuscript by Aulston et al. describes an elegant study in which the authors have investigated whether ...

Alberto Lleó Hospital de Sant Pau ; Posted: 29 Feb 2024 This impressive study characterizes the longitudinal biomarker changes in sporadic AD. The pattern of changes in other forms of AD, such as ...

Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

In mice, APOE3-Christchurch reduced amyloidosis, tauopathy, and tau spreading. Two copies of APOE4-Christchurch staved off tangles, gliosis, and neurodegeneration. Just one copy reduced gliosis and ...

24 Oct 2023. People with ApoE3 Christchurch variant stave off even autosomal-dominant Alzheimer’s disease by keeping neurofibrillary tangles at bay. Could people born without this protective mutation ...

Dennis Selkoe Co-Director, Brigham and Women's Hospital's Ann Romney Center for Neurologic Diseases; Posted: 31 Aug 2023 I am against offering a direct-to-consumer Aβ42/40 blood test for individuals ...

12 Aug 2023. Aliria Rosa Piedrahita de Villegas surprised scientists when she remained sharp 30 years past her expected age of Alzheimer’s disease onset, as dictated by an autosomal-dominant E280A ...

12 May 2023. Otsuka Pharmaceutical Co. Ltd. and Lundbeck LLC announced on May 10 that their D2 dopamine receptor agonist, brexpiprazole, aka Rexulti, had been approved by the U.S. Food and Drug ...